RELATED CONTENT
Navidea Biopharmaceuticals announced the completion of the sale of its Lymphoseek product to Cardinal Health. Navidea received approximately $83 million at closing, and will have the opportunity to earn up to $227 million of contingent consideration based on certain milestones through 2026, with $17.1 million of that amount guaranteed over the next three years.
March 08, 2017 
Navidea Biopharmaceuticals Inc. announced that it has executed a Letter of Intent (LOI) with Cardinal Health for the sale of all rights, title and interest to Navidea’s Lymphoseek product. The agreement covers all U.S. Food and Drug Administration (FDA)-approved, pending and future oncology diagnostic indications in North America, subject to certain limitations, as well as certain other related assets. Under the terms of the LOI, Navidea would receive $80 million at closing, with future consideration tied to annual sales of the Lymphoseek product and certain sales-based milestones. Total consideration to Navidea would be capped at $310 million.
September 06, 2016 At the surface, the term “advanced visualization†seems nebulous at best. Medical imaging technology continues to develop and advance at a rapid rate, so determining what qualifies as advanced remains a moving target as well. In general, however, the current cutting edge of imaging centers around 3-D/4-D viewing and mobile technology, with different specialties implementing them in unique ways.
June 04, 2015 June 15, 2012 — At the Society of Nuclear Medicine’s (SNM) 59th Annual Meeting in Miami Beach, Fla., June 9-12, Cardinal Health introduced new technology enhancements that make it possible for hospital nuclear medicine departments and imaging centers to seamlessly improve data integration and the overall efficiency of their operations.
June 15, 2012 
June 10, 2011 — At the Society of Nuclear Medicine’s 58th Annual Meeting in San Antonio, June 4-8, Cardinal Health previewed The Center for the Advancement of Molecular Imaging (The Center), its new, first-of-its-kind innovation laboratory, which it plans to open in July 2011.
June 20, 2011 
August 3, 2009 - Cardinal Health today announced it has agreed to acquire the assets of privately held Biotech, an operator of Positron Emission Tomography (PET) cyclotrons and nuclear pharmacies in the Southwestern United States, as it pursues more growth opportunities in PET imaging agents.
August 03, 2009 September 29, 2008 - Cardinal Health today revealed plans for a tax-free spin-off of its clinical and medical products ...
September 28, 2008 June 16, 2008 - Cardinal Health will open three additional Positron Emission Tomography (PET) radiopharmaceutical ...
June 15, 2008 June 16, 2008 - Cardinal Health will now manufacture, compound and distribute Positron Emission Tomography (PET) ...
June 15, 2008 June 9, 2008 - Cardinal Health today launched a new system that leverages the company’s dispensing technologies to ...
June 08, 2008